Group 1 - The Hang Seng Innovative Drug Index has increased by over 65% year-to-date, leading all industry indices in Hong Kong stocks [1][3] - Among the top 20 stock ETFs by net value increase this year, 17 are Hong Kong pharmaceutical-themed ETFs, with returns exceeding 46%, outperforming the 18th position held by gold stock ETFs by 10 percentage points [3] - The top five positions in the net value increase ranking are all occupied by Hong Kong innovative drug-themed ETFs, each with a net value increase of over 60% year-to-date [3] Group 2 - On June 10, several Hong Kong pharmaceutical-themed ETFs saw significant trading volume, with 11 ETFs having a turnover rate exceeding 100%, the highest reaching 281.60% [3] - Despite the overall net outflow of over 4 billion yuan from Hong Kong pharmaceutical-themed ETFs year-to-date, some ETFs like the Huatai-PB Hang Seng Innovative Drug ETF and the Yinhua Hong Kong Innovative Drug ETF experienced substantial growth in share volume, exceeding 200% and 188% respectively [3] - Institutions generally have a positive outlook on the long-term trend of the innovative drug sector, although caution is advised regarding potential local bubbles [3]
港股创新药板块强势领跑 主题ETF净值涨幅霸榜
Huan Qiu Wang·2025-06-11 02:32